Table 2.
Summary of clinical studies involving the use of isolated hADSCs on craniomaxillofacial defects for the last 10 years.
| Target Disorder | No. of Patients Treated (Age: Mean ± SD) |
ADSC Type | ADSC Delivery |
Study Outcome |
Year | Ref. No. | |
|---|---|---|---|---|---|---|---|
| 1 | Calvarial defects | 4 (63.8: 59–75) 1 | Autologous, derived from abdominal fat | ADSCs containing betaTCP 2 granules were laid on the dura | No complications with satisfactory ossification | 2011 | [73] |
| 2 | Craniofacial microsomia |
7 (12.10 ± 2.20) | Autologous, derived from abdominal fat | Subcutaneous injection in a form of ADSC-enriched fat | Significant increase of surviving fat volume | 2013 | [74] |
| 3 | Cranio-Maxillofacial hard-tissue defects | 13 (53.23 ± 10.29) | Autologous, derived from abdominal fat | ADSC seeded resorbable scaffolds were implanted | Successful integration of the construct in 10 of the 13 cases. | 2014 | [75] |
1 In this study, age was presented as mean with the range, 2 beta-tricalcium phosphate (betaTCP).